The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year.
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment.
Avalo Therapeutics Appoints Steven J. Boyd As Chairman Of Board
On December 14, 2021, the board of directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Steven J. Boyd, a current non-employee director of the Board, as Chairman of the
RBC Capital Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $6
RBC Capital analyst Gregory Renza initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Outperform rating and announces Price Target of $6.
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
53 Biggest Movers From Yesterday
Gainers
DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share.